Last updated: May 24, 2026
PENNSAID (diclofenac epolamine) is a topical nonsteroidal anti-inflammatory drug (NSAID) for osteoarthritis pain and is sold in the US under an FDA-approved NDA. For a clinical trials update and forward market projections, the needed inputs are not available in the provided information set.
What clinical trials are ongoing for PENNSAID (diclofenac epolamine) and what are their results?
No complete clinical-trials dataset is available to enumerate PENNSAID studies (NCT numbers, designs, endpoints, top-line results, enrollment status, and publication trail) in a way that supports a defensible “update” section.
Which indications are being studied beyond osteoarthritis pain?
No indication-level clinical development information is available.
Are there new formulation or delivery-system trials for PENNSAID?
No formulation-specific trial records are available.
What is the market size, demand drivers, and pricing outlook for topical diclofenac epolamine (PENNSAID)?
No verified market sizing, payer trend data, channel mix, or pricing/discount metrics are available to build an evidence-based market view.
Where does PENNSAID sit in the topical NSAID competitive set?
No comparative market-share or prescribing-volume figures are available to rank PENNSAID against other topical diclofenacs or topical NSAID classes.
What reimbursement and formulary dynamics affect PENNSAID sales?
No formulary or reimbursement evidence is available.
When does PENNSAID lose exclusivity and what generic entry risks exist for diclofenac epolamine topical products?
A launch/entry-risk assessment requires Orange Book patent/Exclusivity data tied to the specific listed drug and NDA. That dataset is not provided, so an accurate exclusivity and generic-risk view cannot be produced.
What patents protect PENNSAID in the US and what dosage forms are covered?
No Orange Book listing and patent coverage table is available.
How strong is the patent estate for PENNSAID versus other topical diclofenac products?
No patent estate mapping is available.
Is there Paragraph IV litigation tied to PENNSAID?
No litigation records are available.
What is the FDA regulatory status of PENNSAID and what approvals matter for competition?
A correct regulatory status section requires: NDA status, latest FDA approval dates, listed strengths/dosage forms, labeling history, and any supplements that impact exclusivity or substitutability. None of that information is available.
What is the Orange Book status of PENNSAID?
No Orange Book status data is available.
Has FDA approved any proposed generic or AB-rated equivalents to PENNSAID?
No ANDA status or AB-rating evidence is available.
How does PENNSAID compare with other topical diclofenac products (e.g., diclofenac gel/solution) on efficacy, safety, and labeling?
A comparison requires head-to-head trial evidence or consistent endpoint extraction across products plus labeling-specific dosing instructions and warnings. No structured clinical or label evidence is available.
What do key pharmacokinetic and systemic exposure differences imply for safety?
No PENNSAID-specific PK/SAM exposure data is available.
What commercial projection scenarios apply to PENNSAID through the next 3 to 7 years?
A defensible projection requires a baseline revenue figure, expected formulary behavior, generic entry timing, and adoption curves by indication and geography. None of these inputs are available.
Base case, downside, and upside assumptions for PENNSAID
No validated assumptions are available to define scenarios.
Revenue impact from potential generic entry or formulation substitution
No entry-timing or substitution evidence is available.
Which regions contribute most and how does geography affect pricing?
No geography-specific sales distribution is available.
Key Takeaways
No data-backed clinical update, market sizing, exclusivity/generic risk, regulatory status, or revenue projections for PENNSAID can be produced from the information provided.
FAQs
- What is the FDA-approved indication and dosing schedule for PENNSAID diclofenac epolamine?
- What topical NSAIDs are direct competitors to PENNSAID, and how do their labels differ?
- What does the Orange Book list for PENNSAID regarding patents and exclusivity?
- Have any ANDAs been filed for PENNSAID, and are any Paragraph IV challenges involved?
- How do topical diclofenac systemic exposure differences affect GI, cardiovascular, and renal safety risk?
References
-
